Press releaseGlobe Newswire
Rein Therapeutics
RNTX · NASDAQ
$0.5951+$0.0431 (+7.81%)TodayMarket closed ·
Prev close $0.552
Latest news
- Press releaseGlobe Newswire
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- NewsAvi Kapoor
Why Twilio Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- Press releaseGlobe Newswire
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
- Press releaseGlobe Newswire
Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis
- News
UK MHRA Authorizes Rein Therapeutics To Initiate Phase 2 "RENEW" Clinical Trial Of LTI-03, For Idiopathic Pulmonary Fibrosis
- Press releaseGlobe Newswire
Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
- Press releasePRNewswire
XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration
- Press releaseGlobe Newswire
Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing
- Press releasePRNewswire
Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- NewsAvi Kapoor
Why RH Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
Rein Therapeutics Doses First Patient in Phase 2 Trial for IPF Drug LTI-03
- Press releasePRNewswire
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF
- Press releasePRNewswire
Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference
- Press releasePRNewswire
Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
- Press releasePRNewswire
Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF
- Press releasePRNewswire
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF
- Press releasePRNewswire
Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025
- Press releasePRNewswire
Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference
- Press releasePRNewswire
Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases
- Press releasePRNewswire
Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F
- Press releasePRNewswire
Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- Press releasePRNewswire
Aileron Therapeutics Announces Rebranding to Rein Therapeutics
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.